Juan-Pablo Mas

Alpheus Medical, Inc, is a privately held company based in Oakdale, Minnesota, developing a novel sonodynamic therapy platform targeting solid body cancers. The company’s lead product utilizes a novel, non-invasive drug device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM). Alpheus Medical’s work has been developed in conjunction with some of the most accomplished names worldwide in neuro-oncology, and with support from the American Cancer Society and National Brain Tumor Society.

Oncology, AI, genomics, proteomics, radiomics, ML, diagnostics

Exo (pronounced “Echo”) is a medical imaging software and devices company. Exo believes everyone around the world should have access to high-quality, affordable and easy-to-use medical imaging. The company is on a mission to modernize medical imaging through its high-performance ultrasound platform and artificial intelligence. Exo’s goal is to enable healthcare professionals to make critical, real-time decisions that ultimately improve patient outcomes. Our powerful ecosystem combines high-performance imaging, FDA-cleared AI and workflow software thats designed to make medical imaging as simple as using a smartphone.

A solution for patients suffering from heart failure with pulmonary hypertension.

SomosVC is a 501(c)(3) non-profit organization focused on unlocking opportunities for Latino/a VC investors, developing a community that leaves a lasting impact on the ecosystem. Our mission is simple: to accelerate and elevate the presence of Latinos/as in venture capital. We believe that when venture investors are empowered to show up as their authentic selves, the flow of capital from limited partners to venture capitalists and ultimately to startup founders becomes more diversified, impactful, and representative of U.S. demographics.

We are a clinical-stage, privately held medical technology company developing a transformational neuromodulation platform to treat diseases of undesired neural activity.

Saluda Medical is a global company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders. The company’s first product, the Evoke® System, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system and is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain. The Evoke System instantaneously reads, records, and responds to the nerves’ response to stimulation to provide continually optimized therapy and is proven to be superior to open-loop SCS for the treatment of overall trunk and/or limb pain. 12-month results from the EVOKE Study, the first double-blind randomized controlled trial (RCT) used in support of Premarket Approval (PMA) in spinal cord stimulation history, were published in The Lancet Neurology and 24-month results have since been published JAMA Neurology. Both studies are poised to set new clinical standards for long-term pain relief and improvements in physical and emotional functioning, sleep quality and health-related quality of life. In the EU, Evoke is CE Marked and commercially available. In the U.S., Evoke is FDA-approved and will be available when the Company implements its full commercial release in 2023. Saluda Medical is a privately held company with headquarters in Artarmon, New South Wales, Australia and has offices in Bloomington, MN, USA; Harrogate, UK; and Terheijden, Netherlands. To learn more about Saluda Medical, including the risks & important safety information, visit www.saludamedical.com.

Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urgency Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera’s minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.

Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health’s wearable therapy is essential tremor, a disease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

SetPoint Medical is developing novel bioelectronic medicine therapies to treat those who suffer from autoimmune diseases such as rheumatoid arthritis, Crohn's Disease and multiple sclerosis. The company has developed a proprietary and innovative bioelectronic medicine platform consisting of a micro-regulator programmed via a unique prescription pad based interface. This novel therapy has the potential to provide patients and healthcare providers with a safe and efficacious alternative to drugs, while costing payers significantly less than biologic therapies.

Alpheus Medical, Inc, is a privately held company based in Oakdale, Minnesota, developing a novel sonodynamic therapy platform targeting solid body cancers. The company’s lead product utilizes a novel, non-invasive drug device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM). Alpheus Medical’s work has been developed in conjunction with some of the most accomplished names worldwide in neuro-oncology, and with support from the American Cancer Society and National Brain Tumor Society.

Who We Are: AdvaMeds member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. Our members produce health care technology both in the United States and around the world. AdvaMed members range from the largest to the smallest medical technology innovators and companies. Our Mission: AdvaMed advocates for a legal, regulatory and economic environment that advances global health care by assuring worldwide patient access to the benefits of medical technology. We promote policies that foster the highest ethical standards, rapid product approvals, appropriate reimbursement, and access to international markets. To achieve this, AdvaMed promotes: Speedier product approvals by industry regulators worldwide; More timely coverage and payment determinations globally; Fair access to international markets; and Effective communications about the value of medical technology to key audiences including legislators, regulators, medical societies and patient organizations.

Oncology, AI, genomics, proteomics, radiomics, ML, diagnostics

Mobia Medical, Inc. (formerly MicroTransponder, Inc.) is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Companys breakthrough Vivistim® Paired VNS™ System is the first FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Vivistim Paired VNS Therapy combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. For more information, visit Vivistim.com and review safety information at Vivistim.com/safety.

Rock Health accelerates innovation at the nexus of technology and healthcare through an early-stage venture fund, an enterprise strategy group, and a non-profit advancing equity-centered change.